![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pegylated Interferon-Lambda (PegIFN-λ) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12
|
|
|
Reported by Jules Levin
46th EASL Congress, Berlin, Germany
March 30-April 3, 2011
S Zeuzem, S Arora, B Bacon, T Box, M Charlton, M Diago, D Dieterich, R Esteban Mur, G Everson, M Fallon, P Ferenci, R Flisiak, J George, R Ghalib, N Gitlin, A Gladysz, S Gordon, S Greenbloom, T Hassanein, I Jacobson, L Jeffers, K Kowdley, E Lawitz, S Lee, B Leggett, S Lueth, D Nelson, P Pockros, M Rodriguez-Torres, V Rustgi, L Serfaty, M Sherman, M Shiffman, R Sola, M Sulkowski, H Vargas, J Vierling, B Yoffe, L Ishak, D Fontana, D Xu, J Lester, T Gray, A Horga, J Hillson, E Ramos, JC Lopez-Talavera, A Muir, on behalf of the EMERGE Study Group
![EASL1.gif](../images/040311/040311-1/EASL1.gif)
![EASL2.gif](../images/040311/040311-1/EASL2.gif)
![EASL3.gif](../images/040311/040311-1/EASL3.gif)
![EASL4.gif](../images/040311/040311-1/EASL4.gif)
![EASL5.gif](../images/040311/040311-1/EASL5.gif)
![EASL6.gif](../images/040311/040311-1/EASL6.gif)
![EASL7.gif](../images/040311/040311-1/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|